18 Jul 2019 --- The US Food and Drug Administration (FDA) needs to assert a more active role in regulating consumer health and safety with regard to cannabis use. This is according to comments filed by the Center for Science in the Public Interest (CSPI) to the agency. The consumer group notes that the decriminalization and legalization of cannabis occurring at the state level is producing a legal patchwork with inadequate policies and funding to protect consumers. Cannabinoids (CBD) and the risks they may pose are also poorly understood.
.jpeg)
